LON:DXRX

Diaceutics (DXRX) Share Forecast, Price & News

GBX 98.10

-5.90 (-5.67%)

(As of 10:52 AM ET)

Compare

Today's Range: 98.10
▼
104
50-Day Range: 93
▼
109
52-Week Range: 74
▼
118

Volume: 26,474 shs
Average Volume: 56,527 shs
Market Capitalization: £82.87 million

P/E Ratio: 10,500.00
Dividend Yield: N/A
Price Target: GBX 150

Profile Analyst Ratings Chart Competitors Insider Trades Headlines

About Diaceutics (LON:DXRX) Stock

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX lab education, a suite of tailored and targeted training sessions designed to provide essential education for labs to enable and drive quality testing and biomarker knowledge; DXRX advisory boards that create and enable a valuable interface for pharmaceutical companies with a view to exploring and revealing new insights pertinent to the commercialisation and development of a therapy or companion diagnostic; and DXRX Lab Alerts, an advanced laboratory targeting service delivering tailored, short-form, quick read, educational messages with call-to-action to labs in the DXRX network. In addition, it offers implementation and consulting services for precision medicine diagnostics. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.

DXRX Price History

30 days | 90 days | 365 days | Advanced Chart

DXRX Stock News Headlines

September 27, 2023 | americanbankingnews.com

Diaceutics (LON:DXRX) Receives "Buy" Rating from Canaccord Genuity Group

April 20, 2023 | finance.yahoo.com

Diaceutics PLC (LON:DXRX) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead

October 4, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.

April 20, 2023 | finance.yahoo.com

Diaceutics PLC (LON:DXRX) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

April 17, 2023 | marketwatch.com

Diaceutics 2022 Pretax Profit Rose on Growing Demand

March 13, 2023 | marketwatch.com

Diaceutics Suspends Share Trading as SVB Closure Restricts Access to Its Funds

March 10, 2023 | finance.yahoo.com

Those who invested in Diaceutics (LON:DXRX) a year ago are up 13%

January 28, 2023 | finance.yahoo.com

Broker Revenue Forecasts For Diaceutics PLC (LON:DXRX) Are Surging Higher

October 4, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

January 27, 2023 | lse.co.uk

TRADING UPDATES: Diaceutics wins two deals; Faron proposes placing

December 9, 2022 | finance.yahoo.com

An Intrinsic Calculation For Diaceutics PLC (LON:DXRX) Suggests It's 40% Undervalued

November 28, 2022 | msn.com

Danske Bank supported the purchase of the new building at Kings Hall Life Sciences Park

September 29, 2022 | finance.yahoo.com

Edited Transcript of DXRX.L earnings conference call or presentation 28-Sep-22 12:00pm GMT

September 16, 2022 | nz.finance.yahoo.com

DEWA and WGEO Complete Preparations for 8th Edition of the World Green Economy Summit

September 16, 2022 | yahoo.com

Bake Off star Laura Adlington reveals she was left suicidal after trolls fat-shamed her on social media

August 14, 2022 | uk.finance.yahoo.com

Diaceutics PLC (DXRX.L)

July 2, 2022 | finance.yahoo.com

Is Diaceutics PLC (LON:DXRX) Trading At A 32% Discount?

June 13, 2022 | lse.co.uk

Diaceutics wins USD2 million contract with "top five global" drug firm

May 23, 2022 | finance.yahoo.com

Diaceutics PLC (LON:DXRX) Has Varied Financials: Could That Be Why Its Recent Performance Has Been Uneventful?

May 5, 2022 | lse.co.uk

Diaceutics inks five-year deal with existing pharma partner

April 7, 2022 | finance.yahoo.com

The past year for Diaceutics (LON:DXRX) investors has not been profitable

March 22, 2022 | lse.co.uk

Diaceutics returns to pretax profit in 2021 and ups revenue

March 16, 2022 | marketwatch.com

Diaceutics Approved by US Agency to Receive Enhanced Data

February 14, 2022 | marketwatch.com

Diaceutics Gets Three-Year Contract Worth More Than $2.5 Mln

January 25, 2022 | uk.news.yahoo.com

Is this FTSE AIM stock primed for growth in 2022?

January 11, 2022 | lse.co.uk

Diaceutics hails DXRX platform for strong annual sales and earnings

January 11, 2022 | marketwatch.com

Diaceutics Appoints Nick Roberts CFO, 2021 Revenue rose 10%

See More Headlines

Receive DXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Diagnostics & Research
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:DXRX
CUSIP: N/A
CIK: N/A
Web: www.diaceutics.com
Phone: N/A
Fax: N/A
Employees: 151
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: GBX 150
High Stock Price Forecast: GBX 150
Low Stock Price Forecast: GBX 150
Forecasted Upside/Downside: +44.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 10,500.00
Forward P/E Ratio: 33.44
P/E Growth: N/A
Net Income: N/A
Net Margins: 0.03%
Pretax Margin: N/A
Return on Equity: 0.01%
Return on Assets: -0.72%

Debt

Debt-to-Equity Ratio: 3.07
Current Ratio: 7.99
Quick Ratio: 9.92

Sales & Book Value

Annual Sales: £21.90 million
Price / Sales: 4.01
Cash Flow: GBX 33.34 per share
Price / Cash Flow: 3.12
Book Value: GBX 49 per share
Price / Book: 2.12

Miscellaneous

Outstanding Shares: 84,470,000
Free Float: N/A
Market Cap: £87.85 million
Optionable: Not Optionable
Beta: 0.36

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Peter Keeling (Age 61)
Founder, CEO & Exec. Director
Comp: $363.24k

Mr. Nicholas Stewart Roberts (Age 40)
CFO & Director
Comp: $180.37k

Mr. Ryan Keeling (Age 40)
Chief Innovation Officer & Exec. Director
Comp: $334.27k

Ms. Julie Browne
Chief Operating Officer

Ms. Gillian Shaw
Gen. Counsel

Ms. Jillian Beggs
VP of Sales & Marketing

Ms. Norma Thompson
Global Head of HR

Mr. Jordan Clark
Chief Commercial Officer

Ms. Susanne Munksted
Chief Precision Medicine Officer

Ms. Marieke Hoefsmit
Sr. Director & Head of Data Delivery Netherlands

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

DXRX Stock - Frequently Asked Questions

Should I buy or sell Diaceutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diaceutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DXRX shares.
View DXRX analyst ratings or view top-rated stocks.
What is Diaceutics' stock price forecast for 2023?: 2 brokers have issued twelve-month price objectives for Diaceutics' shares. Their DXRX share price forecasts range from GBX 150 to GBX 150. On average, they anticipate the company's stock price to reach GBX 150 in the next twelve months. This suggests a possible upside of 44.2% from the stock's current price.
View analysts price targets for DXRX or view top-rated stocks among Wall Street analysts.
How have DXRX shares performed in 2023?: Diaceutics' stock was trading at GBX 75.50 at the start of the year. Since then, DXRX shares have increased by 37.7% and is now trading at GBX 104.
View the best growth stocks for 2023 here.
What is Diaceutics' stock symbol?: Diaceutics trades on the London Stock Exchange (LON) under the ticker symbol "DXRX."

How do I buy shares of Diaceutics?: Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Diaceutics' stock price today?: One share of DXRX stock can currently be purchased for approximately GBX 104.
How much money does Diaceutics make?: Diaceutics (LON:DXRX) has a market capitalization of £87.85 million and generates £21.90 million in revenue each year.
How many employees does Diaceutics have?: The company employs 151 workers across the globe.

This page (LON:DXRX) was last updated on 10/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial